This systematic review aimed to evaluate existing comparative studies regarding the impact of semaglutide compared to another GLP-1 RA (liraglutide and efinopegdutide) in facilitating weight reduction and safety profile in patients with obesity [5]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.